Form 4: IMMUNIC CMO Granted Over 2.3 Million Stock Appreciation Rights

IMMUNIC, INC.'s Chief Medical Officer, Andreas Muehler, was granted 2,310,000 Stock Appreciation Rights (SARs) with an exercise price of $0.77, exercisable from August 1, 2026, subject to various conditions.

Summary

• Andreas Muehler, Chief Medical Officer of IMMUNIC, INC. (IMUX), was granted a total of 2,310,000 Stock Appreciation Rights (SARs) on July 16, 2025.
• Each SAR has an exercise price of $0.77 and an expiration date of July 16, 2035.
• The SARs become exercisable beginning August 1, 2026.
• The SARs are intended to be settled for shares of IMMUNIC's common stock, provided the company obtains stockholder approval to amend its 2019 Omnibus Equity Incentive Plan to support stock settlement.
• If stockholder approval is not obtained, the SARs could be settled for cash.
• The exercisability of specific tranches of SARs is contingent upon the exercise of the Issuer's Series A and Series B purchase warrants by their holders.
• The exercisability of other SAR tranches is contingent upon the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second and third tranches of the January 4, 2024 private placement.

Sentiment

Score: 7

Explanation: The grant of SARs is generally positive as it aligns executive incentives with shareholder value. However, the multiple conditions for exercisability and stock settlement introduce some uncertainty, slightly tempering the positive sentiment.

Positives

• The grant of a significant number of Stock Appreciation Rights to the Chief Medical Officer aligns management's long-term incentives with shareholder value, as the SARs' value increases with the company's stock price.
• The intention to settle SARs in common stock, pending shareholder approval, could reduce potential future cash outflows for compensation.

Negatives

• The exercisability and settlement of the SARs are subject to multiple conditions, including stockholder approval for plan amendment, warrant exercises, and completion of private placement tranches, introducing uncertainty.
• Failure to obtain stockholder approval for the plan amendment could result in cash settlement of SARs, potentially impacting the company's liquidity.

Risks

• Risk that stockholder approval for amending the 2019 Omnibus Equity Incentive Plan may not be obtained, which could prevent stock settlement of SARs.
• Risk that the Issuer's Series A and Series B purchase warrants may not be exercised by their holders, impacting the exercisability of certain SAR tranches.
• Risk that the second and third tranches of the January 2024 private placement may not be completed, affecting the exercisability of other SAR tranches.
• Potential for dilution if the SARs are settled in common stock, contingent on shareholder approval and other conditions.

Future Outlook

The future settlement of these Stock Appreciation Rights in common stock is contingent upon obtaining stockholder approval to amend the 2019 Omnibus Equity Incentive Plan to provide sufficient shares. Exercisability is also tied to future events such as the exercise of Series A and B warrants and the completion of the second and third tranches of the January 2024 private placement.

Management Comments

• "The Stock Appreciation Rights ('SARs') could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ('Common Stock') provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."

Industry Context

Granting Stock Appreciation Rights is a common executive compensation practice in the biotechnology and pharmaceutical industries, designed to align executive incentives with long-term company performance and shareholder value. The conditions tied to warrant exercises and private placements suggest ongoing financing activities, which are typical for development-stage biotech companies seeking capital for research and development.

Comparison to Industry Standards

• The use of performance-based equity awards like Stock Appreciation Rights for executive compensation is consistent with industry standards in the biotechnology sector, aiming to incentivize executives based on company performance.
• The specific conditions for exercisability, such as those tied to warrant exercises and private placement tranches, are unique to IMMUNIC's current financing strategy and reflect its specific capital structure and funding milestones, making direct comparisons to other companies' specific equity grants challenging without detailed knowledge of their financing activities.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if the SARs are settled in common stock, contingent on shareholder approval. However, the grant also aligns the Chief Medical Officer's interests with shareholder value creation.
• Employees: While this specific grant is to a key executive, the underlying 2019 Omnibus Equity Incentive Plan affects all employees eligible for equity incentives. The proposed amendment could impact the overall pool of shares available for future grants.

Next Steps

• IMMUNIC, INC. needs to obtain stockholder approval to amend its 2019 Omnibus Equity Incentive Plan to allow for stock settlement of the SARs.
• The exercise of the Issuer's Series A and Series B purchase warrants by their holders is a prerequisite for the exercisability of certain SAR tranches.
• The completion of the second and third tranches of the January 2024 private placement, involving the issuance of Common Stock or pre-funded warrants, is required for the exercisability of other SAR tranches.

Key Dates

Keywords

IMMUNIC, IMUX, Stock Appreciation Rights, SARs, Executive Compensation, Insider Transaction, SEC Form 4, Equity Incentive Plan, Private Placement, Warrants, Biotechnology